JPMorgan Chase & Co. Purchases 3,263,822 Shares of Natera, Inc. $NTRA

JPMorgan Chase & Co. lifted its holdings in Natera, Inc. (NASDAQ:NTRA) by 44.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,625,785 shares of the medical research company’s stock after purchasing an additional 3,263,822 shares during the quarter. JPMorgan Chase & Co. owned 7.78% of Natera worth $1,795,125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Bank of Jackson Hole Trust purchased a new position in Natera in the 1st quarter worth about $29,000. TCTC Holdings LLC grew its stake in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after acquiring an additional 106 shares during the period. Hilltop National Bank purchased a new position in shares of Natera during the second quarter valued at approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Natera during the second quarter valued at approximately $36,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares in the company, valued at approximately $28,957,407.36. The trade was a 52.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roy D. Baynes sold 7,668 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the completion of the transaction, the director directly owned 18,359 shares of the company’s stock, valued at $4,095,525.72. This represents a 29.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 236,116 shares of company stock valued at $45,800,290 over the last 90 days. 5.63% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Barclays raised their price target on Natera from $210.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Canaccord Genuity Group upped their price objective on Natera from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Stephens boosted their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $220.29.

Natera Stock Performance

NASDAQ:NTRA opened at $230.63 on Friday. The stock has a 50-day simple moving average of $186.27 and a two-hundred day simple moving average of $167.81. The firm has a market capitalization of $31.83 billion, a PE ratio of -100.71 and a beta of 1.75. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $235.89.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period last year, the business earned ($0.26) EPS. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.